QuidelOrtho Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
$0.78next fiscal year
Monitoring Framework
Key Performance Indicators
Total Reported Revenue Quarterly620MTarget: $2.70 Billion to $2.75 Billion
Adjusted EBITDA Margin Quarterly17.5%Target: Approximately 23%
Free Cash Flow Quarterly-67MTarget: $100 Million to $120 Million
Watch Items
- China NHSA IVD Pricing GuidelinesTrigger: Finalization and implementation timeline of the NHSA reimbursement rate reductionsAction: Assess impact on China distributor sales and adjust commercial pricing strategies accordingly
- Optimization Plan Cost SavingsTrigger: Cumulative pre-tax charges of ~$100 million to achieve $50 million in net savings by 2027Action: Monitor facility consolidation (e.g., Raritan shutdown), procurement initiatives, and distribution rationalization
- LEX VELO System CommercializationTrigger: U.S. commercial launch in late 2026 with measurable assay pull-through in early 2027Action: Track instrument placements and regulatory approvals for global expansion
Research as of 20 Jun 2026